The GALAXY Study: Unlocking the Power of Postoperative ctDNA in Rectal Cancer
The battle against rectal cancer is evolving, and a new study shines a light on the potential of postoperative ctDNA as a game-changer. This research, part of the Japanese GALAXY study, delves into the role of ctDNA in predicting recurrence risk and treatment outcomes for stage II-III rectal cancer patients who undergo upfront surgery.
The Challenge:
While postoperative ctDNA has proven its worth in colorectal cancer, rectal cancer data often comes with a twist. Many studies involve patients who have received neoadjuvant therapy or TNT, making it tricky to interpret the results. This study takes a different approach, focusing on patients who underwent surgery without prior therapy, offering a clearer picture of ctDNA's potential.
Study Design and Methods:
The GALAXY study, conducted in Japan, included 250 patients with pathologically confirmed stage II-III rectal cancer who underwent curative-intent surgery. The key was postoperative ctDNA testing using Signatera, a personalized PCR-NGS assay tailored to each patient's tumor and normal cells. Plasma samples were analyzed for tumor-specific variants, with ctDNA-positive results defined by the detection of ≥2 variants above a specific threshold.
Blood collection followed a strategic timeline, starting with a critical MRD window (2-10 weeks post-surgery) before adjuvant chemotherapy. This was followed by regular surveillance with assessments at 3 and 6 months, ensuring ongoing monitoring.
Unveiling the Power of ctDNA:
The study revealed ctDNA's remarkable ability to predict recurrence and treatment benefit:
Sharp Risk Stratification: In the MRD window, ctDNA positivity within 2-10 weeks post-surgery separated patients into high-risk and low-risk groups. Only 14.2% of patients were ctDNA-positive during this period, but their disease-free survival was significantly worse (HR 9.96, P<0.0001). This translated to a stark difference in 12-month DFS, with 35.0% in ctDNA-positive patients versus 89.5% in ctDNA-negative patients.
Long-Term Risk Prediction: The risk-stratifying power of ctDNA persisted and intensified over time. ctDNA positivity at 3 and 6 months post-surgery remained strongly linked to recurrence (HR 7.98 and 15.16, respectively). During the surveillance period, any ctDNA positivity carried a 25-fold higher recurrence risk compared to serially ctDNA-negative patients.
Predicting Treatment Benefit: ctDNA wasn't just a prognostic marker; it predicted adjuvant chemotherapy benefit. Among ctDNA-negative patients in the MRD window, ACT didn't offer a significant DFS advantage (HR 0.59). In contrast, ctDNA-positive patients experienced a 72% reduction in recurrence risk (HR 0.28) and improved median DFS with ACT.
Molecular Conversion: The study highlighted the importance of serial ctDNA monitoring. Patients who converted from negative to positive ctDNA status faced a significantly increased recurrence risk (HR 8.22), while those persistently positive had the highest risk (HR 45.48). This underscores the need for ongoing ctDNA assessment.
Site-Specific Nuance: Lung metastases presented an interesting pattern. Early post-surgery ctDNA negativity was observed, likely due to lower ctDNA shedding from pulmonary lesions. While many patients eventually became ctDNA-positive, this finding emphasizes the need for cautious interpretation of early negative results in high-risk lung-only relapse scenarios.
Key Insights:
- Postoperative MRD ctDNA is a powerful predictor of recurrence risk in rectal cancer, with hazard ratios indicating significant differences.
- ctDNA's predictive value extends beyond prognosis, with ACT benefit concentrated in MRD-positive patients.
- Serial ctDNA testing offers valuable information, potentially enabling earlier intervention before imaging.
Conclusion:
For stage II-III rectal cancer treated with upfront surgery, postoperative ctDNA is a robust biomarker, strongly predicting recurrence and identifying patients who benefit from adjuvant chemotherapy. This study paves the way for personalized treatment approaches based on ctDNA status and dynamics, while acknowledging the need for region-specific considerations and randomized trials for widespread adoption.
